U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.41%)
     
  • USD/JPY

    108.7830
    +0.0670 (+0.06%)
     
  • BTC-USD

    56,844.39
    -5,351.15 (-8.60%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Recro Pharma, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton; Investors Who Lost Money Should Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, May 11, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has launched an investigation into potential securities fraud by Recro Pharma Inc. (REPH) and certain of its officers. Investors who have lost money are encouraged to contact the firm for a free case evaluation.

Recro Pharma today reported worse-than-expected financial results for the first quarter and revised its 2020 revenue guidance down from a range of $97-100 million to a range of $80-85 million. In revising its guidance, Recro Pharma cited several factors, including: (1) increased competition by one of the Company’s key customer’s competitors, (2) slower than expected new business growth primarily attributable to COVID-19, and (3) notifications by two customers of discontinuations for two commercial product lines.

On this news, shares of Recro Pharma common stock plummeted by approximately 40%, down from an opening price of $8.42 per share to close at just $5.08 per share.

If you purchased or acquired shares of Recro Pharma and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockesq.com, or at https://shareholder.law/recro.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockesq.com
SOURCE: Block & Leviton LLP
www.blockesq.com